Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
ics PLC - novel RNA therapeutics developer with offices in London and Berlin - Says last day of trading of shares on A ...
Silence Therapeutics PLC 26 November 2021 Silence Therapeutics plc: Update on AIM Delisting 26 November 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or...
FTSE Russell 25 November 2021 Silence Therapeutics (UK): Constituent Deletion Changes in FTSE UK Index Series 25 November 2021 Subject to the expected cancellation of trading on AIM for Silence...
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by A ...
Silence Therapeutics PLC 16 November 2021 Silence Therapeutics Reports Third Quarter 2021 Financial Results 16 November 2021 LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("...
Silence Therapeutics PLC 11 November 2021 Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN...
Silence Therapeutics PLC 10 November 2021 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B9GTXM62 Issuer Name SILENCE THERAPEUTICS PLC UK or Non-UK Issuer UK 2...
ics PLC - novel RNA therapeutics developer with offices in London and Berlin - Investment firm Frazier Life Sciences P ...
Silence Therapeutics PLC 05 November 2021 Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN...
Silence Therapeutics PLC 01 November 2021 Results of General Meeting 1 November 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the Company"), a...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
